Physician profile
Dianne Winter
NPI 1972008159
$2,132.79
in general payments reported to CMS, 2019-2025
24 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.54 · 2021: $221 · 2022: $776 · 2023: $573 · 2024: $380 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.02 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $523.19 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $359.96 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $284.92 | 2022-2024 | Freestyle Libre 3, Freestyle Insulinx |
| Lilly USA, LLC | $149.84 | 2021-2024 | Zepbound |
| Rhythm Pharmaceuticals, INC. | $119.57 | 2023 | Imcivree |
| Merck Sharp & Dohme LLC | $108.72 | 2019-2022 | |
| Pfizer INC. | $100.91 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $85.20 | 2021-2025 | Farxiga, Breztri |
| Amgen INC. | $53.24 | 2021-2022 | |
| Cequr Corporation | $40.96 | 2025 | Cequr Simplicity |
| Daiichi Sankyo INC. | $39.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $32.12 | 2021-2022 | |
| Astellas Pharma US INC | $31.60 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $29.83 | 2022 | |
| Glaxosmithkline, LLC. | $28.14 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.71 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.29 | 2021 | |
| Boston Scientific Corporation | $16.82 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.24 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.05 | 2025 | |
| Phathom Pharmaceuticals, INC. | $15.55 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $15.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.11 | 2022 | |
| Genentech USA, INC. | $14.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dianne Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.